Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Doxorubicin (DOX) induced cardiotoxicity is a major problem during chemotherapy of cancers. DOX-mediated suppression of type 1 IGF receptor (IGF-1R) signaling leads to cardiac dysfunction. Neferine, a bisbezylisoquinoline alkaloid from the seed embryos of Nelumbo nucifera Gaertn possesses a distinct range of pharmacological properties. Herewith, the present study attempts to elucidate the protective role of neferine against DOX induced toxicity in H9c2 rat cardiomyoblast cell line model. DOX-treated H9c2 cells significantly increased mitochondrial superoxide generation, depleted cellular antioxidant status, suppressed the activation of IGF-1R signaling via PI3K/Akt/mTOR and induced autophagy by the activation of ULK1, Beclin1, Atg7, and LC3B. Neferine pre-treatment activated IGF-1R signaling, improved cellular antioxidant pool, increased the expression of down-stream targets of IGF-1R, such as PI3K/Akt/mTOR, inhibited mitochondrial superoxide generation and autophagy significantly with the induction of Nrf2 translocation and expressions of HO1 and SOD1. Our study suggests the use of neferine for amelioration of DOX-mediated cardiotoxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jcb.26305 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.
Clin Cancer Res
September 2025
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Purpose: Pretreatment specimens from patients treated on the I-SPY2 neoadjuvant breast cancer trial were studied to identify prespecified biomarkers associated with response to the regimen of paclitaxel, the anti-type I insulin-like growth factor receptor (IGF-1R) antibody ganitumab, and metformin (PGM) followed by doxorubicin and cyclophosphamide (AC) compared with control therapy (paclitaxel followed by AC). The primary endpoint of this trial is pathologic complete response (pCR).
Experimental Design: One hundred six patients treated with PGM and 119 contemporary controls were evaluated using laser capture microdissection and reverse-phase protein array to evaluate 32 prespecified potential predictive biomarkers in the IGF-1R pathway and 109 additional exploratory endpoints.
UNRAVELLING THE PATHOGENIC MECHANISMS IN GRAVES' ORBITOPATHY.
Eur Thyroid J
September 2025
Department of Medicine I, Johannes Gutenberg University (JGU) Medical Centre, Mainz, Germany.
Graves' orbitopathy (GO) is characterized by orbital inflammatory infiltration, expansion of orbital tissues due to de novo adipogenesis and over-production of hydrophilic glycosaminoglycans, as well as myofibroblastic differentiation resulting in tissue fibrosis. Thyrotropin receptor antibody (TSH-R-Ab) is the major stimulus, which activates Thyrotropin receptor (TSH-R) / insulin-like growth factor-1 receptor (IGF-1R) and its downstream signalling in orbital fibroblasts (OF). Clinical evaluation of TSH-R-Ab, the specific biomarker of Graves' disease (GD) and the associated orbitopathy, provides important clinical information concerning diagnosis, disease monitoring and prognosis of GO.
View Article and Find Full Text PDFMechanisms of IGF1R signaling in type 2 diabetes-related neurodegeneration and therapeutic implications of exercise.
Eur J Med Res
August 2025
Department of Neurology, The Third Affiliated Hospital of Southern Medical University, No. 183, Zhongshan Road West, Guangzhou, Guangdong, China.
Background: Type 2 diabetes (T2D) is a chronic metabolic disorder associated with an elevated risk of neurodegenerative diseases (NDs), notably Alzheimer's disease (AD). The insulin-like growth factor 1 receptor (IGF1R) plays a key role in both T2D and ND pathogenesis by regulating neuroinflammation and neuronal survival. However, the precise molecular mechanisms linking T2D to NDs remain unclear.
View Article and Find Full Text PDFRedefining Treatment Paradigms in Thyroid Eye Disease: Current and Future Therapeutic Strategies.
J Clin Med
August 2025
Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Thyroid eye disease (TED) is a rare autoimmune orbital disorder predominantly associated with Graves' disease. It is characterized by orbital inflammation, tissue remodeling, and potential visual morbidity. Conventional therapies, particularly systemic glucocorticoids, offer only partial symptomatic relief, failing to reverse chronic structural changes such as proptosis and diplopia, and are associated with substantial adverse effects.
View Article and Find Full Text PDFA Novel Serum-Based Bioassay for Quantification of Cancer-Associated Transformation Activity: A Case-Control and Animal Study.
Diagnostics (Basel)
August 2025
Center for Prevention and Therapy of Gynecological Cancers, Department of Research, Hualien Tzu Chi Hospital, Hualien 97004, Taiwan.
: The detection of ovarian cancer remains challenging due to the lack of reliable serum biomarkers that reflect malignant transformation rather than mere tumor presence. We developed a novel biotest using an immortalized human fallopian tube epithelial cell line (TY), which exhibits anchorage-independent growth (AIG) in response to cancer-associated serum factors. : Sera from ovarian and breast cancer patients, non-cancer controls, and ID8 ovarian cancer-bearing mice were tested for AIG-promoting activity in TY cells.
View Article and Find Full Text PDF